Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II study

BACKGROUND: VB-111 is a non-replicating adenovirus carrying a Fas-chimera transgene, leading to targeted apoptosis of tumor vascular endothelium and induction of a tumor-specific immune response. This phase I/II study evaluated the safety, tolerability, and efficacy of VB-111 with and without bevaci...

Descripción completa

Detalles Bibliográficos
Autores principales: Brenner, Andrew J, Peters, Katherine B, Vredenburgh, James, Bokstein, Felix, Blumenthal, Deborah T, Yust-Katz, Shlomit, Peretz, Idit, Oberman, Bernice, Freedman, Laurence S, Ellingson, Benjamin M, Cloughesy, Timothy F, Sher, Naamit, Cohen, Yael C, Lowenton-Spier, Noa, Rachmilewitz Minei, Tamar, Yakov, Niva, Mendel, Itzhak, Breitbart, Eyal, Wen, Patrick Y
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229257/
https://www.ncbi.nlm.nih.gov/pubmed/31844886
http://dx.doi.org/10.1093/neuonc/noz231

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229257/
https://www.ncbi.nlm.nih.gov/pubmed/31844886
http://dx.doi.org/10.1093/neuonc/noz231

Ejemplares similares